Hemogenyx Pharmaceuticals Plc

LSE:HEMO Stock Report

Market Cap: UK£13.0m

Hemogenyx Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of HEMO?
Owner TypeNumber of SharesOwnership Percentage
Private Companies4,1670.119%
Public Companies6,7200.192%
Individual Insiders305,5808.72%
Institutions1,280,18736.5%
General Public1,907,88554.4%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.2%.


Top Shareholders

Top 25 shareholders own 45.07% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.6%
HBOS Investment Fund Managers Limited
370,178UK£1.4m11.1%0.01%
8.48%
IG Group Holdings Plc, Asset Management Arm
297,176UK£1.1m8.7%0.1%
7.06%
Barclays Bank PLC, Wealth and Investment Management Division
247,521UK£915.8k8.93%0.01%
5.36%
Alexis Sandler
187,727UK£694.6k0%no data
3.86%
HSBC Global Asset Management (UK) Limited
135,157UK£500.1k6.78%no data
2.96%
Vladislav Sandler
103,862UK£384.3k0%no data
0.81%
43North LLC
28,429UK£105.2k0%no data
0.79%
Prevail Partners
27,667UK£102.4k0%21.22%
0.71%
Charles Stanley & Co. Ltd, Asset Management Arm
24,835UK£91.9k3.93%no data
0.6%
Jarvis Securities plc, Asset Management Arm
20,898UK£77.3k-53.6%0.01%
0.53%
Fidelity International Ltd
18,642UK£69.0k-3.55%no data
0.4%
Peter Redmond
13,991UK£51.8k0%no data
0.35%
Canaccord Genuity Wealth (International) Ltd.
12,341UK£45.7k0%no data
0.35%
James Brearley & Sons Ltd.
12,158UK£45.0k-42.8%0.02%
0.31%
Integrated Financial Arrangements plc, Asset Management Arm
10,743UK£39.7k11.5%no data
0.28%
UBS Asset Management AG
9,930UK£36.7k30.7%no data
0.27%
Merrill Lynch & Co. Inc., Banking Investments
9,433UK£34.9k0%no data
0.27%
Puma Investment Management Limited
9,357UK£34.6k-68.5%0.02%
0.24%
JPMorgan Chase & Co, Brokerage and Securities Investments
8,471UK£31.3k9.86%no data
0.21%
First Equity Ltd, Asset Management Arm
7,354UK£27.2k0%0.03%
0.19%
Lloyds Banking Group plc
6,720UK£24.9k-13.1%no data
0.18%
Goy Harris Cartwright & Co. Ltd.
6,239UK£23.1k-3.85%0.09%
0.12%
Kippen & Company (Bermuda) Ltd
4,167UK£15.4k0%no data
0.12%
Charles Schwab Investment Management, Inc.
4,149UK£15.4k0%no data
0.068%
Avanza Fonder AB
2,399UK£8.9k31.5%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:59
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hemogenyx Pharmaceuticals Plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution